Physician profile
Andrew D Schultz
NPI 1528110582
$6,739.18
in general payments reported to CMS, 2019-2025
31 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,841 · 2020: $370 · 2021: $1,692 · 2022: $568 · 2023: $449 · 2024: $636 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,978.13 | 2021-2024 | Axonics |
| Boston Scientific Corporation | $1,336.41 | 2019-2025 | Ams 700, Advance Xp, Ams 800 Artificial Urinary Sphincter |
| Neotract INC. | $1,187.06 | 2019-2020 | |
| Astellas Pharma US INC | $466.47 | 2019-2023 | Myrbetriq |
| Coloplast Corp | $290.66 | 2020-2025 | Porges Coloplast, Speedicath |
| Teleflex LLC | $171.47 | 2021-2024 | Urolift |
| Urogen Pharma, INC. | $158.09 | 2024-2025 | |
| Janssen Biotech, INC. | $142.03 | 2019-2025 | Erleada, Akeega, Balversa |
| Sumitomo Pharma America, INC. | $122.13 | 2023-2025 | Orgovyx, Gemtesa |
| Amgen INC. | $82.45 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $81.27 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $77.68 | 2025 | Adstiladrin |
| Abbvie INC. | $76.82 | 2019-2025 | |
| Endo USA, INC. | $71.92 | 2024-2025 | Xiaflex |
| Medtronic, INC. | $58.76 | 2021-2025 | Altaviva |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $53.82 | 2023 | |
| Olympus America INC. | $52.81 | 2025 | Cysto-Nephro Videoscope, Itind System |
| Pfizer INC. | $50.39 | 2019-2024 | |
| Baxter Healthcare | $30.78 | 2023 | Perclot |
| Progenics Pharmaceuticals, INC. | $27.90 | 2023 | Pylarify |
| Medtronic USA, INC. | $25.67 | 2019 | |
| Travere Therapeutics, INC. | $24.35 | 2019 | |
| Novo Nordisk INC | $23.12 | 2025 | Wegovy |
| 180 Medical, INC. | $22.80 | 2020 | |
| Myriad Genetic Laboratories, INC. | $21.25 | 2023 | Prolaris |
| Mayne Pharma Commercial LLC | $20.88 | 2025 | |
| Caldera Medical, INC | $19.50 | 2023 | Desara |
| Myovant Sciences INC. | $17.53 | 2022 | |
| Civco Medical Instruments | $17.09 | 2025 | |
| Dendreon Pharmaceuticals LLC | $15.48 | 2019 | |
| Photocure INC | $14.46 | 2023 | Cysview |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.